Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein discovered in 2003 and playing an important role in lipoprotein metabolism. The main function of PCSK9 is to regulate the number of low-density lipoprotein (LDL) receptors on the surface of hepatocytes. The biological effect of PSCK9 is to reduce the number of LDL receptors on the surface of hepatocytes, which reduces their ability to take up LDL lipoproteins. PCSK9 inhibitors such as alirocumab, evolocumab or inclisiran are a new, very effective method of lipid-lowering therapy. Recently, a number of naturally derived compounds have been identified that are characterized by the ability to reduce the activity of PCSK9. These compounds are among the alkaloids, polyphenols, sterols, stanols, vegetable proteins and other nutrients and may find application in supporting the pharmacotherapy of lipid disorders.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call